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ABSTRACT 
RECQL5 is a member of the RecQ family of DNA helicases and has key roles in homologous 
recombination, base excision repair, replication and transcription. The clinicopathological 
significance of RECQL5 expression in breast cancer is unknown. In the current study we 
have evaluated RECQL5 mRNA expression in 1977 breast cancers, and RECQL5 protein 
level in 1902 breast cancers [Nottingham Tenovus series (n=1650) and ER- cohort (n=252)]. 
Expression levels were correlated to aggressive phenotypes and survival outcomes. High 
RECQL5 mRNA expression was significantly associated with high histological grade 
(p=0.007), HER2 overexpression (p=0.032), ER+/HER2-/high proliferation genefu subtype 
(p <0.0001), integrative molecular clusters (intClust 1and 9) (p <0.0001) and poor survival (p 
<0.0001). In sub-group analysis, high RECQL5 mRNA level remains significantly associated 
with poor BCSS in ER+ cohort (p<0.0001) but not in ER- cohort (p=0.116). At the protein 
level, in tumours with low RAD51, high RECQL5 level was significantly associated with 
high histological grade (p<0.0001), higher mitotic index (p=0.008), de-differentiation (p= 
0.025), pleomorphism (p= 0.027) and poor survival (P=0.003). In sub-group analysis, high 
RECQL5/low RAD51 remains significantly associated with poor BCSS in ER+ cohort 
(p=0.010), but not in ER- cohort (p=0.628). In multivariate analysis, high RECQL5 mRNA 
and high RECQL5/low RAD51 nuclear protein co-expression independently influenced 
survival (p = 0.022) in whole cohort and in the ER+ sub-group. Pre-clinically, we show that 
exogenous expression of RECQL5 in MCF10A cells can drive proliferation supporting an 
oncogenic function for RECQL5 in breast cancer. We conclude that RECQL5 is a promising 
biomarker in breast cancer. 
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Summary: RECQL5 is a member of the RecQ family of DNA helicases and has key roles in 
homologous recombination, base excision repair, replication and transcription. We provide 
the first clinical evidence that RECQL5 expression is associated with aggressive breast 
cancers. 
Key words: RECQL5; breast cancer; biomarker; prognosis; ER positive breast cancer 
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INTRODUCTION 
RecQ helicases are a highly conserved family of proteins with critical roles in the 
maintenance of genomic stability (1-4). RECQL5 is a key member of the mammalian RecQ 
helicase family (1).  It is a 3’-5’ helicase with weak Holiday junction unwinding activity (1). 
RECQL5 preferentially unwinds the lagging strand of DNA at replication fork structures and 
can promote strand exchange in vitro (5). Three isoforms of RECQL5 have been identified; 
RECQL5α (410aa), RECQL5β (435aa) and RECQL5γ (991aa) (6). Whereas RECQL5α and 
RECQL5γ are cytoplasmic, RECQL5β isoform has nuclear localisation (6). RECQL5β (here 
in referred to as RECQL5) interacts with multiple DNA repair and metabolising proteins 
including RAD51, RAD50, PARP1, FEN1, RNA Polymerase II, WRN, BLM and Mre11, 
NBS1, PCNA, TopIIa and Top IIIa/b (1). RECQL5 has important roles in homologous 
recombination (HR), base excision repair (BER), DNA replication and transcription (1). 
Evidence for a role in HR includes findings that RECQL5 deficient cells have an increased 
rate of sister chromatid exchange (7), and that depleted cells accumulate γH2Ax and RAD51 
foci (8). Mechanistically RECQL5’s function in HR can be proposed from in vitro studies 
showing that RECQL5 physically interacts with RAD51, causing an ATPase dependent 
disruption of RAD51 mediated presynaptic filament formation and hence has anti-
recombinase activity (9) similar to Bloom syndrome helicase (BLM) (7). Further RECQL5 
associates with the MRN complex and inhibits MRE11 exonuclease activity (10), which may 
also contribute to the HR function of RECQL5. Interestingly while the MRN complex is 
required to bring RECQL5 to sites of DSBs, it’s recruitment is independent of the helicase 
activity (11). RECQL5 may also have a role in base excision repair (BER). It’s precise 
function in this pathway is not clear but RECQL5 interacts with the long patch BER proteins 
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PCNA and FEN1, it’s interaction stimulating FEN1 activity, and RECQL5 co-localises with 
FEN1 after oxidative damage of DNA (12). In addition the short patch BER protein XRCC1 
is retained at sites of oxidative damage in the absence of RECQL5 and expression of PARP1 
and XRCC1 maybe regulated by RECQL5 (13). A role in protecting cells from DNA 
replication stress has also been shown for RECQL5. RECQL5 foci increase following 
replication stress and overexpressing RECQL5 can overcome thymidine induced replication 
stress (14). Likewise RECQL5 can prevent spontaneous replication fork collapse and 
RECQL5 depleted cells are hypersensitive the DNA replication inhibitor camptothecin, (15, 
16). RECQL5 has also been implicated in regulation of transcription elongation and can 
supress genomic instability associated with transcriptional stress (2, 17, 18).   
Germline mutation of three of the RecQ helicases (BLM, WRN and RECQL4) leads to 
cancer predisposition syndromes namely Bloom syndrome, Werner syndrome and Rothmund-
Thomson syndrome (3, 4). Although RECQL5 helicase has not been associated with any 
disease phenotype, in preclinical studies, RECQL5 deficient mice cells show increased levels 
of spontaneous double strand breaks, are susceptible to gross chromosomal rearrangements 
and are prone to develop lymphomas and various solid tumours including breast cancer (8) 
(19).  
We hypothesised that RECQL5 may influence breast cancer pathogenesis. In the current 
study we have evaluated RECQL5 mRNA expression in 1950 breast cancers, and RECQL5 
protein level in 1902 breast cancers. We provide the first clinical evidence that RECQL5 may 
influence the development of aggressive breast cancer and have prognostic significance 
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particularly in ER+ breast cancers. In addition we show that exogenous expression of 
RECQL5 in MCF10A cells can drive proliferation supporting a oncogenic function for 
RECQL5 in breast cancer. 
MATERIALS AND METHODS 
RECQL5 and mRNA expression: RECQL5 mRNA expression was investigated in 
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort. The 
METABRIC study protocol, detailing the molecular profiling methodology in a cohort of 
1980 breast cancer samples is described by Curtis et al (20).  Patient demographics are 
summarized in supplementary Table S1 of supporting information. ER positive and/or 
lymph node negative patients did not receive adjuvant chemotherapy.  ER negative and/or 
lymph node positive patients received adjuvant chemotherapy. For   this   cohort, the mRNA 
expression   was   hybridized   to   Illumina   HT-12 v3 platform (Bead Arrays), and the data 
were pre-processed and normalized as described previously (20). RECQL5 expression was 
evaluated in this data set (RECQL5 probe ID: ILMN_1697682).  The probe was a perfect 
match and quality for its target, having a GC content of 58% , 0 SNPs and it does not possess 
a polyG tail at the end.  Samples were classified into the intrinsic subtypes based on the 
PAM50   gene   list. A   description   of   the   normalization, segmentation, and statistical 
analyses was previously described (20).   Real time RT-qPCR was performed on the ABI 
Prism 7900HT sequence detection system   (Applied   Biosystems)   using   SYBR1 Green 
reporter.   All   the samples were analysed as triplicates. The Chi-square test was used for 
testing association between categorical variables, and a multivariate Cox model was fitted to 
the data using as endpoint breast cancer specific death.  X-tile (Version 3.6.1) was used to 
identify a cut-off in gene expression values such that the resulting subgroups have 
!  8
significantly different survival courses. In addition, a corrected P-value was produced for 
each analysis by  using  Monte-Carlo  Cross Validation (MCCV) simulations (50 random 
populations) in X-tile to avoid the problem of  over fitting and finding aberrantly low p-value 
due to the analysis of multiple cut-points (21). The two- fold cross validation was used to 
randomly split the data in to two halves and find the optimal cut-point of one half, and then 
divide the other half according to this cut-point. Then, the optimal cut-point of the second 
half was found and the first halve was similarly divided. Finally, a survival analysis of the 
entire dataset was performed based on the average of the  optimal cut-points obtained from 
the MCCV simulations (21). 
RECQL5 protein expression in breast cancer: The study was performed in a consecutive 
series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 
1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. 
Patient demographics are summarised in Supplementary Table S2. This is a well-
characterized series of patients with long-term follow-up that have been investigated in a 
wide range of biomarker studies (22-25).  All patients were treated in a uniform way in a 
single institution with standard surgery (mastectomy or wide local excision), followed by 
Radiotherapy.   Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 
1989, AT was scheduled based on prognostic and predictive factor status, including 
Nottingham Prognostic Index (NPI), oestrogen receptor-α (ER-α) status, and menopausal 
status. Patients with NPI scores of <3.4 (low risk) did not receive AT. In pre-menopausal 
patients with NPI scores of ≥3.4 (high risk), classical Cyclophosphamide, Methotrexate, and 
5-Flurouracil (CMF) chemotherapy was given; patients with ER-α positive tumours were also 
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offered endocrine therapy. Postmenopausal patients with NPI scores of ≥3.4 and ER-α 
positivity were offered endocrine therapy, while ER-α negative patients received classical 
CMF chemotherapy. Median follow up was 111 months (range 1 to 233 months).  Survival 
data, including overall survival, disease-free survival (DFS), and development of loco-
regional and distant metastases (DM), was maintained on a prospective basis.  DFS was 
defined as the number of months from diagnosis to the occurrence of local recurrence, local 
lymph node (LN) relapse or DM relapse.  Breast cancer specific survival (BCSS) was defined 
as the number of months from diagnosis to the occurrence of BC related-death. Local 
recurrence free survival (LRS) was defined as the number of months from diagnosis to the 
occurrence of local recurrence. DM-free survival was defined as the number of months from 
diagnosis to the occurrence of DM relapse.  Survival was censored if the patient was still 
alive at the time of analysis, lost to follow-up, or died from other causes. 
We also evaluated an independent series of 252 ER-α negative invasive BCs diagnosed and 
managed at the Nottingham University Hospitals between 1999 and 2007.  All patients were 
primarily treated with surgery, followed by Radiotherapy and anthracycline chemotherapy. 
The characteristics of this cohort are summarised in supplementary Table S3.  
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al (26), 
were followed throughout this study.  Ethical approval was obtained from the Nottingham 
Research Ethics Committee (C202313).  
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) constructed with 2 replicate 0.6mm cores from the centre and 
periphery of the tumours. The TMAs were immunohistochemically profiled for RECQL5 and 
other biological antibodies (Supplementary Table S4 of supporting information) as 
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previously described (22-25).  Immunohistochemical staining was performed using the 
Thermo Scientific Shandon Sequenza chamber system (REF: 72110017), in combination 
with the Novolink Max Polymer Detection System (RE7280-K: 1250 tests), and the Leica 
Bond Primary Antibody Diluent (AR9352), each used according to the manufacturer’s 
instructions (Leica Microsystems).  Leica Autostainer XL machine was used to dewax and 
rehydrate the slides. Pre-treatment antigen retrieval was performed on the TMA sections 
using sodium citrate buffer (pH 6.0) and heated for 20 minutes at 950C in a microwave 
(Whirpool JT359 Jet Chef 1000W). A set of slides were incubated for 60 minutes with the 
primary anti-RECQL5 antibody (HPA029971, Sigma-Aldrich, UK) and anti-RAD51 
antibody (clone Ab88572, Abcam Ltd., Cambridge, UK), at a dilution of 1:100 and 1:70 
respectively. Negative and positive (by omission of the primary antibody and IgG-matched 
serum) controls were included in each run. The negative control ensured that all the staining 
was produced from the specific interaction between antibody and antigen. 
Evaluation of immune staining: The tumour cores were evaluated by two scorers (AA and 
TAF) and the concordance between the two scorer was excellent (k = 0.79). Whole field 
inspection of the core was scored and intensities of nuclear staining were grouped as follows: 
0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage 
of each category was estimated (0-100%).  H-score (range 0-300) was calculated by 
multiplying intensity of staining and percentage staining. RECQL5, RAD51 and TOPO2A 
expression was categorised based on the frequency histogram distributions. A median H score 
of ≥10 was taken as the cut-off for high RECQL5 and a median H score of ≥8 was taken as 
the cut-off for high RAD51 nuclear expression. For TOPO2A >25% staining cells were taken 
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as high TOPO2A expression. Not all cores within the TMA were suitable for IHC analysis as 
some cores were missing or lacked tumour (<15% tumour).  
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one 
way tests were used. Cumulative survival probabilities were estimated using the Kaplan–
Meier method, and differences between survival rates were tested for significance using the 
log-rank test. Multivariate analysis for survival was performed using the Cox proportional 
hazard model. The proportional hazards assumption was tested using standard log-log plots. 
Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. 
All tests were two-sided with a 95% CI and a p value <0.05 considered significant.  For 
multiple comparisons, p values were adjusted according to Holm-Bonferroni correction 
method (27).  
Breast cancer cell lines and culture: MCF-7 (ER+/PR+/HER2-, BRCA1 proficient), MDA-
MB-231 (ER-/PR-/HER2-, BRCA1 proficient), MDA-MB-468 (ER-/PR-/HER2-, BRCA1 
proficient)  and MDA-MB-436 (ER-/PR-/HER2-, BRCA1 deficient) authenticated cell lines 
were purchased from ATCC and were grown in RPMI (MCF-7, MDA-MB-231) or DMEM 
(MDA-MB-468 and MDA-MB-436) medium with the addition of 10% foetal bovine serum 
and 1% penicillin/streptomycin. Cell lysates were prepared and Western blot analysis 
performed.  Primary anti-RECQL5 antibody (HPA029971, Sigma-Aldrich,UK) was 
incubated over night at room temperature at a dilution of 1:2000. Primary anti-β actin 
antibody (1:10000 dilution [Abcam]) was used as a loading control. Infrared dye-labelled 
secondary antibodies (Li-Cor) [IRDye 800CW Mouse Anti-Rabbit IgG and IRDye 680CW 
Rabbit Anti-Mouse IgG] were incubated at a dilution of 1:10000 for 1 hour.  Membranes 
!  12
were scanned with a Li-Cor Odyssey machine (700 and 800nm) to determine protein 
expression.  
RECQL5 knockdown breast cancer cells using siRNAs: MCF7 cells were transfected with 
50 nM RECQL5 siRNA (Dharmacon, Lafayette, CO) using DharmaFECT 1 reagent 
(Dharmacon, Lafayette, CO) and left for 48 hours.  The cell lysates were prepared and 
western blotted for RECQL5 as above but immunoreactive protein was visualized using ECL 
reagents (Amersham Pharmacia) following manufacturer’s instructions.  The sequences used 
for Q5β-1 and Q5β-3 siRNA constructs were 5’-UGAAGAAGGUGGCCGAUAU-3’ and 5’-
CUGCAAAUGUUGUGGUCAA-3’ respectively. 
RECQL5 overexpression in MCF10A cells and proliferation assay: 10,000 MCF10A cells 
were plated into replica wells of 6 well plate and transfected with pcDNA-RECQL5β (a 
generous gift from Dr. Pavel Janscak - Institute of Molecular Cancer Research, University of 
Zurich) or empty vector control. Following trypsinisation to remove cells from the plate live 
cells counted every 24 h post transfection using trypan blue exclusion. In parallel cell lysates 
were prepared and western blotted for RECQL5 as above but immunoreactive protein was 
visualized using ECL reagents (Amersham Pharmacia) following manufacturer’s instructions. 
Quantitative real time PCR: Total RNA was extracted from MCF-7, MDA-MB-231, MDA-
MB-468 and MDA-MB-436 cells using RNeasy Mini kit (QIAGEN, UK). The quantification 
of the extracted RNA was done using a NanoDrop 2000c Spectrophotometer (Thermo 
Scientific, UK). The cDNA was synthesized from 0.5 µg of total RNA using RT2 first strand 
kit (QIAGEN, UK). qPCR was performed using SYBR Green PCR Master mix (applied 
biosystems,Warrington,UK) with primer set (RECQL5 QuantiTect Prier Assay,Cat. No. 
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QT00084973, QIAGEN) targeting RECQL5 gene. The glyceraldehyde-3-phosphate 
dehydrogenase housekeeper gene was used as an internal control (GAPDH QuantiTect Prier 
Assay, Cat. No. QT00079247, QIAGEN). The real-time PCR for each RNA sample was 
performed in triplicate. NTC (No Template Control) was used to rule out cross contamination 
of reagents and surfaces. NTC included all the RT-PCR reagents except the RNA template. 
Minus reverse transcriptase (- RT) control was used to rule out genomic DNA contamination. 
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RESULTS 
High RECQL5 mRNA levels associate with aggressive sporadic breast cancer: We 
initially profiled a panel of breast cancer cell lines. MDA-MB-436, MDA-MB-468 MCF-7 
and MDA-MB 231 have robust expression of RECQL5 mRNA (Figure 1A). We then 
proceeded to investigate RECQL5 mRNA expression in the METABRIC cohort.  1306/1977 
(66%) of breast tumours had low RECQL5 mRNA expression and 34% (671/1977) of breast 
tumours had high RECQL5 mRNA expression. High RECQL5 mRNA expression was 
significantly associated with aggressive clinicopathological features including high 
histological grade, HER2 over expression, and triple negative phenotypes (ps<0.05) [Table 
1]. High RECQL4 mRNA expression was also found to be significantly correlated to 
previously described breast cancer molecular phenotypes; PAM50.Her2 (p<0.0001) and 
Genufu subtype (ER+/Her2-/High proliferation) (p<0.01) breast tumours [Table 1]. On the 
other hand, PAM50.LumA and Genufu subtypes (ER+/Her2-/low proliferation) were 
associated with low levels of RECQL5 mRNA (ps<0.05) [Table 1]. Interestingly, 
PAM50.Basal was also more common in tumours with low levels of RECQL5 mRNA 
(ps<0.05). Similarly, low RECQL5 mRNA expression was associated with intClust.3 
(p<0.00001) and intClust.4 (ps<0.001) molecular phenotypes that have good prognosis (28). 
However, high RECQL5 mRNA expression was significantly associated with intClust.1 
(p<0.00001), and intClust.9 (p<0.00001) that have intermediate to poor clinical outcome 
(20).  
We then proceeded to survival analysis in METABRIC cohort. High RECQL5 mRNA 
expression was associated with poor breast cancer specific survival (BCSS) (p<0.0001) in the 
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whole cohort [Figure 1B]. In the ER+ sub-group, high RECQL5 mRNA expression was 
found to be associated with poor BCSS (p<0.0001) [Figure 1C]. In the ER+ sub-group that 
received adjuvant endocrine therapy, high RECQL5 mRNA expression remained associated 
with poor BCSS (p<0.001) [Figure 1D]. However, in ER- sub-group, RECQL5 mRNA 
expression did not significantly influence outcome in the ER- cohort, including ER- patients 
who received chemotherapy (p=0.116 and p=0.213 respectively) [Figure 1E, 1F].  
In the multivariate Cox regression analysis, that included other validated prognostic factors, 
RECQL5 mRNA expression was a powerful independent predictor for breast cancer specific 
survival in the whole cohort (p=0.038), ER+ sub-group (p=0.046) but not in the ER- sub-
group (p=0.615) (Table 2).  
Together the data provides evidence that RECQL5 mRNA level has clinicopathological 
significance and influence prognosis, particularly in ER+ breast cancers. We proceeded to 
evaluate RECQL5 protein expression in breast cancers. 
RECQL5 protein expression in sporadic breast cancer: We initially investigated RECQL5 
protein level in breast cancer cell lines and in MCF10A breast epithelial cells. As shown in 
Figure 2A, MDA-MB-436, MDA-MB-468 MCF-7 and MDA-MB 231 have robust 
expression of RECQL5 protein.  On the other hand, in MCF10A cells, RECQL5 expression 
was low compared to MCF7 cells (Figure 2B). When RECQL5 was overexpressed in 
MCF10A (Figure 2B) we observed increased proliferation in RECQL5 overexpressing 
MCF10A cells compared to control MCF10A cells (Figure 2C). Taken together, the data 
suggest that RECQL5 is a marker of proliferation and could have prognostic and/or 
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predictive significance in human breast cancers. We proceeded to IHC investigation in human 
tumours. To provide evidence for the specificity of the anti-RECQL5 antibody used for IHC 
studies, we generated RECQL5 knockdown (KD) MCF7 cells using two siRNA constructs. 
As shown in Figure 2D, control cells have robust RECQL5 expression seen as a single band 
while RECQL5 KD cells show almost complete loss of this band – demonstrating the 
specificity of the RECQL5 antibody.  
We observed nuclear-only localization of RECQL5 protein in breast cancers [Figure 2D]. 
There was no cytoplasmic staining in breast tumours. 46.3% (556/1200) of tumours showed 
low nuclear RECQL5 expression and 53.7% (644/1200) of tumours revealed high nuclear 
RECQL5 expression. We also investigated RECQL5 expression in 30 normal breast tissues. 
There was no cytoplasmic staining in normal tissues. We observed that 30/30 (100%) normal 
tissues showed high nuclear RECQL5 expression. Taken together, the data suggest 
differential expression RECQL5 in normal tissues compared to tumours tissues. We initially 
investigated RECQL5 protein alone in breast cancer tissues. Tumours with low nuclear 
RECQL5 levels were significantly associated with high grade, high mitotic index, tubule 
formation, tumour type, HER2 overexpression, ER-, triple negative and basal type phenotype 
(ps<0.05) [Supplementary Table 5] . In addition, low RECQL5 expression was found to be 
associated with low levels of other DNA repair proteins such as BRCA1, XRCC1, FEN1, 
SMUG1, APE1, Polβ, ATM, ATR, Chk1, Chk2, TOP2A, Rad51, and DNA-PKc (ps< 0.01) 
[Supplementary Table 5]. We then conducted the univariate survival analysis. At protein 
level, RECQL5 expression alone failed to show any statistically significant correlation with 
breast cancer specific survival in whole cohort [Supplementary Figure S1A]. We then 
proceeded to subgroup analysis and again found no statistically significant association with 
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survival in ER+ [Supplementary Figure S1B] and ER- subgroups [Supplementary Figure 
S1C]. As RECQL5 alone, despite having clinicopathological associations with aggressive 
phenotype, did not have prognostic significance we hypothesised that RECQL5 may operate 
in the context of RAD51 or TOPO2A to influence clinical outcomes. We therefore proceeded 
to co-expression analysis.  
RECQL5 co-expression with RAD51 or TOPO2A in sporadic breast cancer: RECQL5 
physically interacts with RAD51 and disrupts RAD51 mediated presynaptic filament 
formation (1, 9). Tumours with high RECQL5-low RAD51 nuclear protein levels were 
significantly associated with high grade, high mitosis and pleomorphism (all p values <0.05) 
[Table 3]. Tumours with low RECQL5-low RAD51 nuclear protein levels were significantly 
associated with tubule formation, NPI>3.4 and ER/PR negativity (all p values <0.05)  [Table 
3]. In univariate analysis, tumours with high RECQL5-low RAD51 nuclear protein levels 
were associated with poor breast cancer specific survival in the whole cohort (p=0.003) 
[Figure 2E]. In sub-group analysis, ER+ tumours with high RECQL5-low RAD51 nuclear 
protein levels were associated with poor breast cancer specific survival (p=0.010) [Figure 
2F]. In ER- cohort, RECQL5-RAD51 co-expression did not influence survival (p=0.628) 
[Supplementary Figure S1D]. We have previously shown a direct interaction between 
RECQL5 and Topoisomerase IIα (TOP2A) where RECQL5 specifically stimulated the 
decatenation activity of TOP2A (29). Tumours with low RECQL5-high TOPO2A were 
significantly associated with high grade, high mitotic index, de-differentiation tumour type, 
high risk NPI and PR negativity (Supplementary Table S6). In univariate analysis, 
RECQL5-TOPO2A co-expression did not influence survival (Supplementary Figures S1E, 
S1F, S1G) 
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In multivariate analysis (Table 4), RECQL5-RAD51 co-expression remained statistically 
significant independent marker of prognosis (p=0.022) in the whole cohort. NPI and HER-2 
expression were other factors independently associated with breast cancer specific survival (p 
values 0.001 and 0.0001 respectively).  In the ER+ sub-group, RECQL5-RAD51 co-
expression was of borderline significance (p=0.07), but not in the ER- sub-group (p=0.172).   
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DISCUSSION 
RECQL5 is a key member of the RecQ family of DNA helicases (1-4). RECQL5 is a 
multifunctional protein with roles in DNA replication, chromosomal segregation, DNA repair 
(including homologous recombination, single strand break repair and base excision repair) 
and transcription. Deficiency of DNA repair factors such as RECQL5 could predispose an 
individual to cancer through increased genomic instability. On the other hand, in established 
tumours high levels of RECQL5 may promote survival of cancer cells that are constantly 
under DNA damaging oxidative stress. RECQL5 deficient mice are predisposed to 
lymphomas and solid tumours including breast tumours (1-4). In humans, polymorphisms 
within the RECQL5 gene may predispose an individual to cancer including: osteosarcomas, 
laryngeal carcinomas and breast cancers (30-33). In a recent study in colorectal cancers, low 
RECQL5 expression was observed at the mRNA and protein levels (19).  The authors 
concluded that RECQL5 deficiency may predispose to colorectal cancer. However, the study 
had several limitations, including a small cohort and lack of clear evidence of 
clinicopathological associations or survival outcomes (19).  
The clinicopathological significance of RECQL5 in sporadic breast cancer is unknown. In the 
current study we have comprehensively evaluated RECQL5, and unravelled its complex role 
in breast cancers. At the mRNA level, we observed high expression in 34% of tumours. High 
RECQL5 mRNA expression was significantly associated with aggressive phenotypes and 
adverse survival. The prognostic significance was particularly pronounced in ER+ sub-group, 
supporting the observation that high RECQL5 mRNA expression was more likely in ER+/
HER2 -/high proliferation Geneufu sub-type tumours. At the protein level, we observed high 
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RECQL5 levels in 53.7% of breast cancers. However it should be pointed out that RECQL5 
mRNA expression and RECQL5 protein expression were investigated in two independent 
cohorts. Therefore a limitation to the current study is that we were unable to perform direct 
correlations between mRNA and protein expression. In contrast to mRNA expression data, 
although low RECQL5 expression was associated with aggressive phenotype, RECQL5 
protein alone did not influence survival outcomes in patients.  The data suggest that RECQL5 
may be subjected to complex post-transcriptional regulation. Alternatively, there may be a 
threshold effect for expression level and this threshold is more accurately measured by the 
analysis of mRNA levels. Another possibility is that the complex role of RECQL5 may 
operate in the context of RAD51. RECQL5 directly interacts with RAD51 (9) and the anti-
recombinogenic role of RECQL5 may be active through disruption of RAD51 mediated 
presynaptic filament formation during HR (34). Therefore, we conducted RECQL5-RAD51 
co-expression studies and observed that tumours with high RECQL5/low RAD51 not only 
manifest aggressive phenotypes but were also associated with poor survival. In sub-group 
studies, similar to mRNA data, the prognostic significance was more pronounced in ER+ 
breast cancer but not in ER- tumours. Consistent with high RECQL5 being associated with 
aggressive phenotypes, over expression of RECQL5 in the normal breast cell line MCF10A 
increased proliferation. Interestingly RAD51 is reported as having relatively low expression 
in MCF10A cells (35)and the functional relationship between RECQL5, RAD51, 
proliferation, recombination and tumourigenesis will be the subject of future investigations. 
Taken together, the data provides the first clinical evidence that RECQL5 may influence 
breast cancer pathogenesis.  
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RECQL5 interacts with and is a general transcription elongation factor for RNA Pol II (2, 17, 
18). Loss of RECQL5 leads to a genome-wide increase in the average rate of gene 
transcription, transcriptional stress and recombination (17) suggesting RECQL5 has a 
function in resolving such stress. RNA polymerases generate positive supercoiling ahead of 
the transcription apparatus, which in turn feeds back to reduce the processional rate of RNA 
polymerase. Topoisomerases are ubiquitous enzymes that remove supercoiling and therefore 
are required for normal transcription elongation. Specifically, type II topoisomerases generate 
transient protein-concealed double strand breaks while removing torsional stress from the 
DNA and collisions with the transcription apparatus can convert these protein-DNA 
complexes into permanent DNA strand breaks (36). Previously, we showed a direct 
interaction between RECQL5 and Topoisomerase IIα (TOP2A) specifically stimulated the 
decatenation activity of TOP2A (29). TOP2A expression is a marker for proliferation and has 
been analyzed in a number of breast cancer studies in part because it lies in close proximity to 
the HER2 gene on chromosome 17.  Therefore, we were interested in evaluating if there were 
any expression correlations between RECQL5, which also resides on chromosome 17 
(17q25.1), and TOP2A expression in our breast cancer cohorts. Interestingly, high grade 
tumours are more often scored as RECQL5- and TOP2A+, than any other expression pattern. 
This may reflect the fact that loss of RECQL5 promotes transcriptional stress. Additionally, 
while TOP2A is known as a marker for proliferation, loss of RECQL5 may make these cells 
more dependent on TOP2A to relieve transcriptional stress. Thus in this subgroup of patients, 
it would be interesting to evaluate the efficacy of TOP2A targeted therapies (such as 
doxorubicin that is routinely used in breast cancer therapy), if in fact these tumours are more 
dependent on topoisomerase activities than other tumour types cells.   
!  22
In conclusion, our data provides evidence that RECQL5 could be a promising biomarker in 
breast cancer and needs further investigation as a potential drug target.  
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Table 1: Association between RecQL5 mRNA expression and clinico-pathologic variables in 
METABRIC cohort. 
VARIABLE RECQL5 mRNA Expression  P Values
Low High
Unadjusted Adjusted
N(%) N (%) 
A) Pathological    Parameters
Lymph node stage 
Negative 684(52.6%) 351(52.5%) 0.990 25.74 
Positive (1-3) 207(15.9%) 107(15.9%)
Positive (>3) 409(31.5%) 213(31.7%)
Grade
G1 129(10.3%) 40(6.2%) 0.007 0.023
G2 512(41.0%) 258(40.2%)
G3 607(48.6%) 343(53.5%)
Tumour Size (cm)
T 1a+b(1.0) 61(4.7%) 31(4.7%) 0.097 0.157
T 1c(>1.0-2.0) 532(41.0%) 234(35.6%)
T2 (>2.0-5) 639(49.2%) 362(55.0%)
T3 (>5) 67(68.4%) 31(31.6%)
NPI
≤ 3.4 461(35.3%) 219(32.6%) 0.238 0.269
>3.4 137(64.7%) 1160(67.4%)
Her2 overexpression (No) 1159(88.7%) 573(85.4%) 0.032 0.075
                              (Yes) 147(11.3%) 98(14.6%)
Triple negative          (No)       1079(82.6) 581 (88.6) 0.023 0.066
                               (Yes) 227(17.4) 90(13.4)
ER                   (Negative) 322(24.7%) 148(22.1%) 0.199 0.246
                       (Positive) 984(75.3%)  523(77.9%)
PgR                  (Negative) 603(46.2%) 333(49.6%) 0.145 0.188
                         (Positive) 703(53.8%) 338(50.4%)
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Bold = Statistically significant;HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor;Triple negative: ER-/PgR-/HER2- . Adjusted 
p values were calculated using Benjamini-Hochberg false discovery rate method to adjust for 
multple testing. 
Genefu subtype
ER-/Her-2 negative 110(16.3%) 40(12.6%) 0.129 0.186
ER+/Her-2 negative/high 
proliferation 229(33.9%) 137(43.1%) 0.005 0.018
ER+/Her-2 negative/low 
proliferation 265(39.1%) 103(32.4%) 0.038 0.082
Her-2 positive 72(10.7%) 38(11.9%) 0.543 0.564
PAM50 subtype
PAM50.Her2 130(11.2%) 108(17.6%) 1.5X10-4 0.0008
PAM50.Basal  233(20.1%) 97(15.8%) 0.029 0.075
PAM50.LumA 488(42.1%) 227(37.1%) 0.042 0.084
PAM50.LumB 309(26.6%) 180(29.4%) 0.214 0.252
IntClust subgroups
intClust.1 49(3.8%) 88(13.1%) 8.3X10-15 0.00001
intClust.2 55(4.2%) 17(2.5%) 0.059 0.102
intClust.3  221(16.9%) 69(10.3%) 7.8X10-5 0.0005
intClust.4 267(20.4%) 76(11.3%) 3.9X10-7 0.00001
intClust.5 120(63.5%) 69(36.5%) 0.433 0.469
intClust.6 50(3.8%) 36(5.4%) 0.113 0.172
intClust.7 113(8.7%) 40.2(11.3%) 0.056 0.104
intClust.8 187(14.3) 113(16.8%) 0.139 0.191
intClust.9 74(5.7%) 72(10.7%)   4.6X10-5 0.0004
intClust.10 170(13.0%) 55(8.2%) 0.001 0.0043
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Table 2. Multivariate analysis of RECQL5 mRNA expression in breast cancer 
Bold: Statistically significant; HR: Hazard Ratio; CI: Confidence interval; LN: Lymph node 
P-Value Risk Ratio 95% CI for Risk Ratio
Lower Upper
Breast Cancer Specific Survival (Whole Cohort)
Grade 0.000004 1.447429 1.237421 1.693079
Size (Cm) 0.000001 1.121003 1.076755 1.167069
LN Status 0.000001 1.875371 1.666800 2.110040
RECQL5 mRNA expression 0.023530 1.223718 1.027549 1.457337
Breast Cancer Specific Survival (ER+ Cohort)
Grade
0.0002 1.411263 1.176981 1.692178
Size (Cm) 0.000001 1.180525 1.123389 1.240566
LN Status 0.000001 1.822326 1.578493 2.103825
RECQL5 mRNA expression 0.045 1.242008 1.004707 1.535359
Breast Cancer Specific Survival (ER- Cohort)
Grade 0.968564 1.008054 0.676448 1.502217
Size (Cm) 0.239188 1.046124 0.970452 1.127695
LN Status 0.000001 1.908038 1.539252 2.365181
RECQL5 mRNA expression 0.635591 1.078023 0.790092 1.470886
!  29
Table 3.  RECQL5 – RAD51 protein co-expression and breast cancer  
   
                    VARIABLE
RECQL5 and RAD51 protein  
co-expression P- value 
(Unadjuste
d)
P -Value 
(Adjuste
d)
RQ5n-/
RAD51n
- 
N (%)
RQ5n+/ 
RAD51n- 
N (%) 
RQ5n-/ 
RAD51
n+ 
N (%) 
RQ5n+/ 
RAD51n+ 
N%
A) Pathological    Parameters
Tumour Size  
 ≤1cm 
 >1-2cm 
 >2-5cm 
>5cm
 12 (6.8) 
77 (43.8) 
84 (47.7) 
3 (1.7)
9 (5.8) 
65 (41.9) 
78 (50.3) 
3 (1.9)
10 (7.6) 
73 
(55.7) 
45 
(34.4) 
3 (2.3)
16 (8.6) 
107 (57.5) 
62 (33.3) 
1 (0.5)
0.031 0.045
Tumour Stage                                 
1 
2 
3 
96 (54.5) 
64 (36.4) 
16 (9.1)
83 (53.2) 
57 (36.5) 
16 (10.3)
79 
(60.3) 
44 
(33.6) 
8 (6.1)
112 (60.2) 
52 (28.0) 
22 (11.8)
0.370 0.401
Tumour Grade                              
 G1 
 G2 
 G3 
 
13 (7.4) 
59 (33.5) 
104 
(59.1)
18 (11.5) 
38 (24.4) 
100 (64.1)
14 
(10.7) 
53 
(40.5) 
64 
(48.9)
37 (19.9) 
73 (39.2) 
76 (40.9)
4.1x10-5 0.0005
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 
10-18) 
M3 (high; mitosis >18)
45 (26.0) 
38 (22.0) 
90 (52.0)
  
34 (22.5) 
28 (18.5) 
89 (58.9)
41 
(31.5) 
24 
(18.5) 
65 
(50.0)
72 (40.0) 
38 (21.1) 
70 (38.9)
0.008 0.017
Tubule Formation                          
1 (>75% definite tubule) 
2 (10%-75% definite 
tubule) 
3 (<10% definite tubule)
5 (2.9) 
45 (26.0) 
123 
(71.1)
2 (1.3) 
49 (32.5) 
100 (66.2)
7 (5.4) 
43 
(33.1) 
80 
(61.5)
7 (3.9) 
75 (41.7) 
98 (54.4)
0.025 0.046
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Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation)
0 (0.0) 
61 (35.5) 
111 
(64.5)
1 (0.7) 
42 (27.8) 
108 (71.5)
2 (1.6) 
48 
(37.2) 
79 
(61.2)
2 (1.1) 
82 (45.6) 
96 (53.3)
0.027 0.043
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others
121 
(69.9) 
21 (12.1) 
7 (4.0) 
14 (8.1) 
3 (1.7)
113 (72.4) 
22 (14.1) 
2 (1.3) 
8 (5.1) 
1 (0.6)
75 
(58.1) 
27 
(20.9) 
3 (2.3) 
13 
(10.1) 
0 (0.0)
102 (55.1) 
50 (27.0) 
0 (0.0) 
20 (10.8) 
1 (0.5)
0.002 0.005
Lymph Node Status                   
Negative 
Positive (1-3) 
Positive (>3)
81 (54.4) 
56 (37.6) 
12 (8.1)
69 (51.1) 
54 (40.0) 
12 (8.9)
72 
(60.0) 
44 
(36.7) 
4 (3.3)
97 (58.4) 
53 (31.9) 
16 (9.6)
0.353 0.417
B) Aggressive Phenotype
Her2 overexpression                     
No 
Yes
153 
(87.4) 
22 (12.6)
123 (80.4) 
30 (19.6)
105 
(81.4) 
24 
(18.6)
159 (88.3) 
21 (11.7)
0.105 0.136
Triple Negative 
Phenotype               
No 
Yes
149 
(84.7) 
27 (15.3)
130 (83.3) 
26 (16.7)
115 
(87.8) 
16 
(12.2)
151 (81.2) 
35 (18.8)
0.457 5.94
NPI           
≤3.4 
>3.4
31 (18.3) 
138 
(81.7)
31 (21.2) 
115 (78.8)
34 
(27.4) 
90 
(72.6) 
68 (38.4) 
109 (61.6)
1.1x10-4 0.0005
C) Hormone Receptors
ER               
Negative 
Positive
60 (35.1) 
111 
(64.9)
53 (34.9) 
99 (65.1)
32 (25.4) 
94 (74.6)
28 (15.7) 
150 (84.3)
7.6x10-5 0.0005
PgR                                   
Negative 
Positive
91 (54.5) 
76 (45.5)
77 (52.0) 
71 (48.0)
49 (39.5) 
75 (60.5)
63 (35.6) 
114 (64.4)
0.001 0.003
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Bold = Statistically significant; HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor; Triple negative: ER-/PgR-/HER2- . Adjusted 
p values were calculated using Benjamini-Hochberg false discovery rate method to adjust for 
multple testing.  
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Table 4. Multivariate analysis of RECQL5-RAD51 protein co-expression in breast cancer 
B P value Exp (B)
95.0% CI for Exp (B)
Lower Upper
Breast Cancer Specific Survival in the whole cohort 
RECQL5-RAD51 co-expression
       
       
-0.069
0.022 0.934 0.880 0.990
NPI 0.769 0.001 2.158 1.378 3.379
ER Status 0.293 0.097 1.340 .949 1.893
HER2 Status 0.728 0.0001 2.071 1.432 2.994
  Breast Cancer Specific Survival in the ER+ cohort 
  RECQL5-RAD51 co-expression -0.063 0.073 0.939 0.876 1.006
   NPI 0.784 0.001 2.190 1.376 3.484
  HER2 Status          
0.848
0.001 2.335 1.448 3.767
  Breast Cancer Specific Survival in the ER- cohort 
RECQL5-RAD51 co-expression -0.081 0.172 0.923 0.822 1.036
NPI 0.651 0.519 1.917 0.265 13.882
HER2 Status 0.551 0.057 1.735 0.984 3.062
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Figure legends 
Figure 1.  A. RECQL5 mRNA expression in breast cancer cell lines. B. Kaplan Meier curves 
showing BCSS (Breast cancer specific survival) based on RECQL5 mRNA expression in the 
whole cohort C. Kaplan Meier curves showing BCSS (Breast cancer specific survival) based 
on RECQL5 mRNA expression in ER+ cohort; D. Kaplan Meier curves showing BCSS 
(Breast cancer specific survival) based on RECQL5 mRNA expression in ER+ cohort that had 
endocrine therapy; E. Kaplan Meier curves showing BCSS (Breast cancer specific survival) 
based on RECQL5  mRNA expression in ER- cohort. F. Kaplan Meier curves showing BCSS 
(Breast cancer specific survival) based on RECQL5 mRNA expression in ER- cohort that had 
chemotherapy. 
Figure 2. A1. Western blot of RECQL5 expression in breast cancer cell lines. A2. MCF10A 
breast cells were transfected with RECQL5 or empty vector and. Extracts were made 48 h 
post transfection and western blotted for RECQL5. RECQL5 level in MCF7 cells is shown 
for comparison.  B. MCF10A breast cells were transfected with RECQL5 or empty vector 
and cell number counted every 24 h. Mean and standard deviation are shown for 3 
independent repeats. ** indicates a statistical significance of P<0.01 at 72 h using Student’s 
T.Test. C. Western blot of RECQL5 expression in MCF-7 (RECQL5 wild-type) and MCF-7 
RECQL5 knock down cell line. D. Microphotograph of RECQL5 protein expression in breast 
tumours.  E. Kaplan Meier curves showing BCSS based on RECQL5-RAD51 co-expression 
in the whole cohort. F. Kaplan Meier curves showing BCSS based on RECQL5-RAD51 co-
expression in ER+ cohort.  
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Supplementary Figure Legends 
Supplementary Figure S1: A. Kaplan Meier curves showing BCSS based on RECQL5- 
expression in the whole cohort. B. Kaplan Meier curves showing BCSS based on RECQL5- 
expression in the ER+ cohort. A. Kaplan Meier curves showing BCSS based on RECQL5- 
expression in the ER- cohort.  D. Kaplan Meier curves showing BCSS based on RECQL5-
RAD51 co-expression in ER- cohort. D. Kaplan Meier curves showing BCSS based on 
RECQL5-TOPO2A co-expression in whole cohort. D. Kaplan Meier curves showing BCSS 
based on RECQL5-TOPO2A co-expression in ER+ cohort. D. Kaplan Meier curves showing 
BCSS based on RECQL5-TOPO2A co-expression in ER- cohort. 
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RQ5n-/TOPO2n+ (n=144) 
RQ5n+/TOPO2n- (n=124) 
RQ5n-/TOPO2n- (n=146) 
RECQL5/TOPO2A co-expression (ER+ Cohort)
Log Rank = 2.688; P = 0.442
RQ5n+/TOPO2n+ (n=147) 
RQ5n-/TOPO2n+ (n=90) 
RQ5n-/TOPO2n- (n=98) 
RQ5n+/TOPO2n- (n=90) 
Log Rank = 4.034; P = 0.258
RQ5n+/TOPO2n+ (n=54) 
RQ5n-/TOPO2n+ (n=49) 
RQ5n-/TOPO2n- (n=41) 
RQ5n+/TOPO2n- (n=33) 
RECQL5/TOPO2A co-expression (ER- Cohort)
Supplementary Table S1:  Clinicopathological characteristics in the METABRIC external validation 
cohort  
Variables N (%)
Age at diagnosis [Median (range)] 61.8 (21.93-96.29)
Tumour size [Median (range)] 23 (1, 182)
NPI [Median (95% CI)] 4.04 (3.99-4.09)
Survival [Median (Months, 95% Cl)] 149 (141-159)
Lymph nodes status 
0 
1 
2 
3 
>3 
1012 
336 
170 
112 
316
ER status 
Positive 
Negative 
1485 
437
PAM50 subtype 
Basal  
HER2  
Luminal A  
Luminal B  
Normal  
Not classified 
322 
238 
714 
484 
188 
6
Adjuvant systemic therapy (AT)
No AT 290
Hormone therapy (HT) 1014
Chemotherapy 226
Hormone + chemotherapy 192
  1
  2
Supplementary Table S2: Clinicopathological characteristics of Nottingham Tenovus series 
Variable n* Cases          (%)
Menopausal status 1650
Pre-menopausal 612          (37.0)
postmenopausal 1038        (63.0)
Tumour Grade (NGS) 1650
G1  306          (18.5)
G2 531          (32.2)
G3  813          (49.3)
Lymph node stage 1650
Negative  1056         (64.0)
Positive (1-3 nodes) 486          (29.5)
Positive (>3 nodes) 108           (6.5)
Tumour size (cm) 1650
T1 a + b (≤1.0) 187         (11.0)
T1 c (>1.0 -2.0) 868         (53.0)
T2 (>2.0-5) 579      (35.0)
T3 (>5) 16         (1.0)
Tumour type 1650
IDC-NST 941         (57)
Tubular 349         (21)
ILC 160        (10)
Medullary (typical/atypical) 41          (2.5)
Others 159        (9.5)
NPI subgroups 1650
Excellent PG(2.08-2.40) Low risk 207         (12.5)
Good PG(2.42-3.40) 331          (20.1)
Moderate I PG(3.42 to 4.4) High risk 488         (29.6)
Moderate II PG(4.42 to 5.4) 395         (23.9)
Poor PG(5.42 to 6.4) 170         (10.3)
Very poor PG(6.5–6.8) 59         (3.6)
Survival at 20 years 1650
Alive and well 1055         (64.0)
Dead from disease 468          (28.4)
Dead from other causes 127         (7.6)
Adjuvant systemic therapy (AT)
  3
* Number of cases for which data were available. 
NPI; Nottingham prognostic index, PG; prognostic group 
No AT 665         (42.0)
Hormone therapy (HT) 642         (41.0)
Chemotherapy 307         (20.0)
Hormone + chemotherapy 46         (3.0)
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Supplemental Table S3: Clinicopathological characteristics of ER- cohort 
* Number of cases for which data were available. 
Variable n* Cases          (%)
Menopausal status 252
Pre-menopausal 122      (48.5)
postmenopausal 130      (51.5)
Tumour Grade (NGS) 252
G1    1         (0.3)
G2   27        (10.6)
G3 224        (89.1)
Lymph node stage 252
Negative   121       (48)
Positive (1-3 nodes)    86       (34)
Positive (>3 nodes)     45      (18)
Tumour size (cm) 252
T1 a + b (≤1.0)  28        (11)
T1 c (>1.0 -2.0) 106       (42)
T2 (>2.0-5) 103       (41)
T3 (>5)  15       (6)
Tumour type 252
IDC-NST 224        (89.0)
Tubular 5            (2.0)
ILC 8            (3.0)
Medullary (typical/atypical) 5            (2.0)
Others 0            (4.0)
NPI subgroups 252
Excellent PG(2.08-2.40) Low risk 0           (0.0)
Good PG(2.42-3.40) 0           (0.0)
Moderate I PG(3.42 to 4.4) High risk 111       (44.0)
Moderate II PG(4.42 to 5.4) 81         (32.0)
Poor PG(5.42 to 6.4) 38         (15.0)
Very poor PG(6.5–6.8) 22         (9.0)
Survival at 5 years 252
Alive and well 176      (70.0)
Dead from disease   73      (29.0)
Dead from other causes    3       (1.0)
  5
NPI; Nottingham prognostic index, PG; prognostic group 
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Supplementary Table S4: Antigens, primary antibodies, clone, source, optimal dilution and scoring 
system used for each immunohistochemical marker. 
Antige
n
Antibo
dy Clone Source
Antigen 
Retrieval
Dilutio
n /  
Incubat
ion 
Time
Distributi
on
Scoring 
system
Cut-offs
BRCA1 BRCA1 MS110
Calbioch
em
Citrate 
pH6
1:100 
60 min
Nuclear
% of 
positive 
cells
<25% 
(negative) 
ATM
Rabbit 
MAb 
anti-
ATM
Y170 Abcam Citrate pH6
1:100 
18 
hours
Nuclear
% of 
positive 
cells
<25% 
(negative) 
XRCC1
Mouse 
MAb 
Anti-
XRCC1
33-2-5 Thermo-scientific
Citrate 
pH6
1:200 
20 min
Nuclear
% of 
positive 
cells
≥10% 
(positive)
APE1
Rabbit 
anti-
APE-1
polyclo
nal
Novus 
Biologica
ls
Citrate 
pH6
1:500 
60 min
Nuclear H-score
>100 
(positive)
SMUG1
Goat 
anti-
SMUG1
polyclo
nal
Acris 
Antibodi
es
Citrate 
pH6
1:200 
15 min
Nuclear H-score
≤35 
(negative)
FEN1
Rabbit 
anti-
FEN1
polyclo
nal
Novus 
Biologica
ls
Citrate 
pH6
1:200 
60 min
Nuclear  
and 
Cytoplas
m
H-score ≤100 
(negative)
P21
Mouse 
MAb 
anti-
p21
SW118
Dako-
Cytomati
on
Citrate 
pH6
1:50 
60 min
Nuclear
% of 
positive 
cells
≥10% 
(positive)
       
Ki67
Mouse 
MAb 
anti-
Ki-67
      
MIB1
Dako-
Cytomati
on
Citrate 
pH6
1:300 Nuclear H-score < 10% (low) 
10-30% 
(moderate) 
>30% (high)
P53
Mouse 
MAb 
anti 
p53
DO7 Novocast
ra
Citrate 
pH6
1: 50 
60 min
Nuclear
% of 
positive 
cells
≤20% 
(negative) 
>20% (High)
Bcl-2
Mouse 
MAb 
anti-
Bcl2
124
Dako-
Cytomati
on
Citrate 
pH6
1:100 
60 min
Cytoplas
m
% of 
positive 
cells
>10% 
(positive
  7
All sections were pre-treated with microwave antigen retrieval using 0.1% citrate buffer (pH 6) 
except for HER2 (no pre-treatment) and EGFR (pre-treated with protease for 10 minutes).   
ER
Mouse 
MAb 
anti-
ER-α
SP1
Dako-
Cytomati
on
Citrate 
pH6
1:150 
30 min
Nuclear Allred score
≥3 
(positive)
ER
Mouse 
MAb 
anti-
ER-α
EP1
Dako-
Cytomati
on
Citrate 
pH6
1:80 
30 min
Nuclear % positive 
cells
≥1% 
positive
PR
Mouse 
MAb 
anti-PR
PgR636
Dako-
Cytomati
on
Citrate 
pH6
1:125 
30 min
Nuclear
% positive 
cells
≥1% 
positive
CK14
Mouse 
MAb 
anti-
Ck14
LL002 Novocastra
Citrate 
pH6
1:40 
60 min
Cytoplas
m
% of 
positive 
cells
≥10% 
(positive)
Ck6
Mouse 
MAb 
anti-
Ck5/6
D5/161
B4
Dako-
Cytomati
on
EDTA pH8
1:100 
60 min
Cytoplas
m
% of 
positive 
cells
≥10% 
(positive)
HER2
Rabbit 
antihu
man c-
erbB2
polyclo
nal
Dako-
Cytomati
on
None
1:400 
60 min
Membran
e
See text See text
TOP2A
Mouse 
MAb KiS1
Dako-
Cytomati
on
Citrate 
pH6 1:150
Nuclear/ 
cytoplasm
% of 
positive 
cells
>25% 
(positive)
RECQL5
Rabbit 
anti 
RecqL5
Polyclo
nal
Sigma- 
Aldrich
Citrate 
pH6 
1:100 
60 min
Nuclear H - Score
≥10 
(positive)
BLM
Rabbit 
anti 
BLM
Polyclo
nal
Novus-
Biologica
ls
Citrate 
pH6 
  1:100 
18 
Hours 
Nuclear/ 
Cytoplas
mic
H- Score
≥50  
(positive)
  8
Supplementary Table S5: RecQL5 and breast cancer  
   
                    VARIABLE
RecQL5 (Nuclear)  Protein 
Expression 
                  
P- values 
(Unadjusted) 
P –Values 
(Adjusted)  
Low 
N (%) 
High 
N (%)
A) Pathological    Parameters
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm
 38 (6.9) 
271 (49.0) 
230 (41.6) 
14 (2.5)
69 (10.7) 
325 (50.6) 
235 (36.6) 
13 (2.0)
0.061 0.09
Tumour Stage                                 
1 
2 
3 
326 (58.8) 
183 (33.0) 
45 (8.1)
400 (62.2) 
181 (28.1) 
62 (9.6)
0.161 0.1982
Tumour Grade                              
 G1 
 G2 
 G3 
 
67 (12.1) 
182 (32.9) 
304 (55.0)
122 (19.0) 
209 (32.6) 
311 (48.4)
0.003 0.008
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18)
172 (31.3) 
97 (17.6) 
281 (51.5)
  
233 (36.5) 
124 (19.4) 
281 (44.0)
0.050 0.075
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule)
27 (4.9) 
155 (28.2) 
368 (66.9)
35 (5.5) 
239 (37.5) 
364 (57.1)
0.002 0.005
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation)
12 (2.2) 
194 (35.3) 
344 (62.5)
18 (2.8) 
245 (38.4) 
375 (58.8)
0.377 0.431
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others
309 (63.4) 
73 (15.0) 
16 (3.3) 
38 (7.8) 
51 (10.5)
322 (59.9) 
51 (22.1) 
6 (1.1) 
13 (9.1) 
26 (7.8)
0.004 0.009
Lymphovascular Invasion                   
No 
Yes
361 (65.9) 
187 (34.1)
421 (66.2) 
215 (33.8)
0.908 43.58
B) Aggressive phenotype 
Her2 overexpression                     
No 
Yes
466 (86.3) 
74 (13.7)
567 (90.6) 
59 (9.4)
0.022 0.036
Triple Negative Phenotype               
No 
Yes
420 (78.1) 
118 (21.9)
516 (82.8) 
107 (17.2)
0.041 0.065
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Basal Like Phenotype           
No 
Yes
446 (85.3) 
77 (14.7)
532 (89.3) 
64 (10.7)
0.045 0.069
Cytokeratin 6 (CK6)                                  
Negative 
Positive
391 (82.1) 
85 (17.9)
440 (84.1) 
83 (15.9)
0.402 0.448
Cytokeratin 14 (CK14)                                                                     
Negative 
Positive
410 (87.2) 
60 (12.8)
451 (86.7) 
69 (13.3)
0.814 0.831
Cytokeratin 18 (CK18)                                   
Negative 
Positive
54 (12.2) 
388 (87.8) 
44 (9.1) 
442 (90.9)
0.117 0.161
Cytokeratin 19 (CK19)                                   
Negative 
Positive
36 (7.6) 
440 (92.4)
27 (5.2) 
495 (94.8)
0.121 0.161
C) Hormone receptors 
ER               
Negative 
Positive
171 (31.3) 
375 (68.7)
150 (23.8) 
480 (76.2)
0.004 0.008
PgR                                   
Negative 
Positive
245 (46.9) 
483 (53.1)
249 (42.0) 
344 (58.0)
0.097 0.137
AR                     
Negative 
Positive 
191 (42.4) 
259 (57.6)
166 (33.7) 
327 (66.3)
0.006 0.011
D) DNA Repair 
BRCA1                     
Absent 
 Normal
103 (26.0) 
293 (74.0)
67 (15.1) 
377 (84.9)
8.4x10-6 0.00001
XRCC1                             
Low 
High
91 (22.1) 
320 (77.9)
49 (10.7) 
408 (89.3)
5.0x10-6 0.00001
FEN1                   
Low 
High
292 (78.5) 
80 (21.5)
295 (69.1) 
132 (30.9)
0.003 0.007
SMUG1                  
Low 
High 
176 (48.4) 
188 (51.6) 
141 (33.6) 
279 (66.4)
2.6x10-5 0.0001
APE1 
Low 
High
292 (63.8) 
166 (36.2)
213 (39.7) 
324 (60.3)
1.0x10-6 0.00001
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Bold = Statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human epidermal growth factor 
receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; Basal-like: ER-, HER2 and 
positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER-/PgR-/HER2- . Adjusted p values were 
calculated using Benjamini-Hochberg false discovery rate method to adjust for multple testing. *Fischer test 
was used to obtain p values where one or more of cells has an expected frequency of five or les 
Pol β 
Low 
High 
221 (45.9) 
261 (54.1)
189 (33.3) 
378 (66.7)
3.5x10-5 0.0001
ATR  
Low 
High
344 (74.1) 
120 (25.9)
315 (60.7) 
204 (39.3)
8.0x10-6 0.00001
ATM  
Low 
High
195 (57.4) 
145 (42.6)
187 (48.4) 
199 (51.6)
0.016 0.027
DNA-PKcs  
Low 
High
200 (45.9) 
236 (54.1)
133 (26.7) 
365 (73.3)
1.0x10-6 0.00001
TOP2A                    
Low 
Overexpression 
204 (53.1) 
180 (46.9)
164 (37.6) 
272 (62.4)
8.0x10-6 0.00001
pCHK1 (Cytoplasmic)                       
Low 
High
214 (38.6) 
341 (61.4)
188 (29.2) 
456 (70.8)
0.001 0.003
CHK2                       
Low 
High
230 (57.2) 
172 (42.8)
168 (38.4) 
270 (61.6)
1.0x10-6 0.00001
RecQL4   (Nuclear)                         
Low 
High 
279 (71.2) 
113 (28.8)
209 (47.3) 
233 (52.7)
2.7x10-12 0.00001
RecQL4 (Cytoplasmic)                      
Low 
High 
230 (58.8) 
161 (41.2)
204 (46.4) 
236 (53.6)
0.00033 0.001
BLM (Nuclear)                      
Low 
High 
170 (37.0) 
290 (63.0)
85 (16.5) 
429 (83.5)
4.5x10-13 0.00001
BLM (Cytoplasmic)                      
Low 
High 
355 (77.2) 
105 (22.8)
355 (16.5) 
155 (30.4)
0.008 0.014
RAD51 (Nuclear)                      
Low 
High 
176 (57.3) 
131 (42.7)
156 (45.6) 
186 (54.4)
0.003 0.007
RAD51 (Cytoplasmic)                      
Low 
High 
15 (4.9) 
292 (95.1)
25 (7.4) 
311 (92.6)
0.180 0.211
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Supplementary Table S6:  RECQL5 – TOPO2 co-expression and breast cancer  
   
                    VARIABLE
RecQL5 (Nuclear) & TOPO2(Nuclear) Protein  
Co-Expression P- value 
(Unadjuste
d)
P- value 
(Adjusted)
RQ5n-/
TOPO2n- 
N (%)
RQ5n+/ 
TOPO2n- 
N (%) 
RQ5n-/ 
TOPO2n
+ 
N (%) 
RQ5n+/ 
TOPO2n+ 
N%
Tumour Size  
 ≤1cm 
 >1-2cm 
 >2-5cm 
>5cm
15 (7.2) 
103 
(49.3) 
88 (42.1) 
3 (1.4)
13 (7.9) 
76 (46.3) 
72 (43.9) 
3 (1.8)
10 (5.5) 
90 
(49.5) 
78 
(42.9) 
4 (2.2)
25 (9.1) 
144 (52.6) 
103 (37.6) 
2 (0.7)
0.743 9.659
Tumour Stage                                 
1 
2 
3 
126 
(60.3) 
72 (34.4) 
11 (5.3)
98 (59.4) 
50 (30.3) 
17 (10.3)
108 
(59.3) 
51 
(28.0) 
23 
(12.6)
171 (62.2) 
78 (28.4) 
26 (9.5)
0.231 0.301
Tumour Grade                              
 G1 
 G2 
 G3 
 
31 (14.8) 
79 (37.8) 
99 (47.4)
30 (18.3) 
51 (31.1) 
83 (50.6)
  
14 (7.7) 
44 
(24.2) 
124 
(68.1)
51 (18.5) 
90 (32.7) 
134 (48.7)
2.4X10-4 .001
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 
10-18) 
M3 (high; mitosis >18)
66 (32.2) 
44 (21.5) 
95 (46.3)
  
60 (37.5) 
21 (13.1) 
79 (49.4)
43 
(24.0) 
26 
(14.5) 
110 
(61.5)
101 (37.4) 
47 (17.4) 
122 (45.2)
0.006 0.015
Tubule Formation                          
1 (>75% definite tubule) 
2 (10%-75% definite 
tubule) 
3 (<10% definite tubule)
10 (4.9) 
78 (38.0) 
117 
(57.1)
9 (5.6) 
66 (41.3) 
85 (53.1)
4 (2.2) 
35 
(19.6) 
140 
(78.2)
11 (4.1) 
97 (35.9) 
162 (60.0)
9.1X10-5 0.0012
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation)
4 (2.0) 
82 (40.0) 
119 
(58.0)
1 (0.6) 
56 (35.0) 
103 (64.4)
1 (0.6) 
50 
(28.2) 
126 
(71.2)
5 (1.9) 
104 (38.5) 
161 (59.6)
0.121 0.174
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
Mixed NST/Lobular/Special 
Type
126 
(61.2) 
45 (21.8) 
5 (2.4) 
12 (5.8) 
3 (1.5) 
15 (7.3)
105 (64.4) 
36 (22.1) 
3 (1.8) 
10 (6.1) 
2 (1.2) 
7 (4.3)
128 
(71.9) 
10 (5.6) 
9 (5.1) 
21 
(11.8) 
2 (1.1) 
8 (4.5)
166 (61.0) 
67 (24.6) 
2 (0.7) 
25 (9.2) 
3 (1.1) 
9 (3.3)
1.4X10-4 0.0009
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Bold = Statistically significant; HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; 
PgR: progesterone receptor; Triple negative: ER-/PgR-/HER2- . Adjusted p values were calculated using 
Benjamini-Hochberg false discovery rate method to adjust for multple testing.  
Lymph Node Status                   
Negative 
Positive (1-3) 
Positive (>3)
107 
(57.8) 
69 (37.3) 
9 (4.9)
88 (57.9) 
51 (33.6) 
13 (8.6)
99 
(60.7) 
47 
(28.8) 
17 
(10.4)
149 (61.1) 
73 (29.9) 
22 (9.0)
0.364 0.430
Her2 overexpression                     
No 
Yes
175 
(85.8) 
29 (14.2)
136 (85.5) 
23 (14.5)
145 
(80.1) 
36 
(19.9)
243 (89.0) 
30 (11.0)
0.072 0.134
Triple Negative 
Phenotype               
No 
Yes
171 
(81.8) 
38 (18.2)
144 (87.3) 
21 (12.7)
150 
(82.4) 
32 
(17.6)
223 (81.1) 
73 (18.9)
0.385 0.417
NPI           
≤3.4 
>3.4
58 (28.6) 
145 
(71.4)
47 (30.9) 
105 (69.1)
31 
(18.5) 
137 
(81.5) 
96 (36.5) 
167 (63.5)
0.001 0.003
ER               
Negative 
Positive
58 (28.7) 
144 
(71.3)
42 (25.9) 
120 (74.1)
60 (34.1) 
116 
(65.9)
63 (23.7) 
203 (76.3)
0.107 0.174
PgR                                   
Negative 
Positive
86 (42.4) 
114 
(57.6)
72 (47.1) 
81 (52.9)
87 (51.2) 
83 (48.8)
100 (37.7) 
165 (62.3)
0.036 0.038
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!  35
